FTH (Faeth Therapeutics) EPS (Diluted): $-142.72 (TTM As of Mar. 2026)


FTH Faeth Therapeutics Inc FTH
21 GF Score
Price $24.54
! 2 Warning Signs
View Full Analysis

What is Faeth Therapeutics EPS (Diluted)?

Faeth Therapeutics FTH +0.70% 21 EPS (Diluted) is $-142.72 as of Mar. 2026. GuruFocus rates FTH with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Faeth Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $-131.45. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-142.72.

Faeth Therapeutics's EPS (Basic) for the three months ended in Mar. 2026 was $-131.45. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-142.72.

Faeth Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was $-131.45. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $-142.70.

During the past 3 years, the average EPS without NRIGrowth Rate was 19.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Faeth Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 62.00% per year. The lowest was -20.50% per year. And the median was 4.90% per year.

Faeth Therapeutics  (NAS:FTH) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Faeth Therapeutics EPS (Diluted) Related Terms

Faeth Therapeutics EPS (Diluted) Historical Data

* Premium members only.

The historical data trend for Faeth Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faeth Therapeutics EPS (Diluted) Chart

Faeth Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Diluted)
Get a 7-Day Free Trial -26.60 -31.60 -24.40 -24.01 -16.72

Faeth Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.45 -3.91 -3.62 -3.74 -131.45

FTH vs NEUP, KYNB, CRVO: EPS (Diluted) Comparison

For the Biotechnology subindustry, Faeth Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Faeth Therapeutics PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faeth Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Faeth Therapeutics's PE Ratio falls into.


FTH
21GF Score
Faeth Therapeutics Inc FTH
EPS (Diluted) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faeth Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Faeth Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2025 is calculated as

Diluted EPS (A: Dec. 2025 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-21.085-0)/1.261
=-16.72

Faeth Therapeutics's Diluted EPS for the quarter that ended in Mar. 2026 is calculated as

Diluted EPS (Q: Mar. 2026 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-170.236-0)/1.295
=-131.46

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-142.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Diluted) →
What does a EPS (Diluted) of $-142.72 mean?
Faeth Therapeutics (FTH) has a EPS (Diluted) of $-142.72 as of Mar. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Faeth Therapeutics and its competitors.
Is Faeth Therapeutics' EPS (Diluted) too high?
Faeth Therapeutics' current EPS (Diluted) is $-142.72. Overall, Faeth Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Faeth Therapeutics' EPS (Diluted) compare to NEUP and KYNB?
Faeth Therapeutics' EPS (Diluted) of $-142.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Biotechnology company?
A good EPS (Diluted) depends on the Biotechnology industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Faeth Therapeutics and its competitors. Faeth Therapeutics's current EPS (Diluted) is $-142.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faeth Therapeutics stock overvalued right now?
Faeth Therapeutics (FTH) has a current EPS (Diluted) of $-142.72. The current EPS (Diluted) is $-142.72. Faeth Therapeutics' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Faeth Therapeutics (FTH), the current EPS (Diluted) is $-142.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faeth Therapeutics Business Description

Address 701 Tillery Street No. 12, No.1010, Austin, TX, USA, 78702
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
21GF Score

Get the complete analysis for FTH

EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.54
Price